Clinical Trials Browser

INDUSTRY × Neoplasms, Plasma Cell × Dexamethasone × Clear all

NCT03984097 2026-03-10

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Phase 1 Active not recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05651932 2026-02-10

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06152575 2026-02-03

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Phase 3 Recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02899052 2025-08-05

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT04782687 2025-01-16

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell

NCT03530683 2024-09-03

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

Phase 1 Terminated

LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Plasma Cell

NCT00017069 2020-10-05

Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma

Phase 2 Terminated

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01497093 2020-04-07

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1 Completed

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01023308 2020-03-17

PANORAMA-1

Phase 3 Completed

767 enrolled 17 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT02103335 2017-11-22

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

Phase 1 Completed

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00150462 2017-05-02

Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies

Phase 1 Completed

48 enrolled 26 charts

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Neoplasms, Plasma Cell

NCT01522872 2016-06-02

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

Phase 1/2 Unknown

Hypoxia, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00402181 2014-05-14

An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell